- Home
- DEC vs CGEM Comparison
DEC vs CGEM Comparison
Compare DEC & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DEC | CGEM |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 873.4M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DEC | CGEM |
|---|---|---|
| Price | $15.77 | $14.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $22.00 | ★ $30.11 |
| AVG Volume (30 Days) | ★ 1.2M | 755.4K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | ★ 311.06 | N/A |
| EPS | ★ 4.58 | N/A |
| Revenue | ★ $1,829,142,000.00 | N/A |
| Revenue This Year | $23.30 | N/A |
| Revenue Next Year | N/A | $5.20 |
| P/E Ratio | $3.39 | ★ N/A |
| Revenue Growth | ★ 141.54 | N/A |
| 52 Week Low | $11.21 | $5.68 |
| 52 Week High | $18.90 | $16.74 |
Technical Indicators
Market Signals| Indicator | DEC | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 47.55 | 55.17 |
| Support Level | $14.04 | $11.43 |
| Resistance Level | $16.09 | $15.66 |
| Average True Range (ATR) | 0.68 | 0.88 |
| MACD | -0.28 | 0.04 |
| Stochastic Oscillator | 7.52 | 69.97 |
Price Performance
Historical ComparisonAbout DEC Diversified Energy Company plc
Diversified Energy Co is an independent energy company focused on natural gas and liquids production, transportation, marketing and well retirement, located within the Appalachian and Central regions of the United States. Its principal focus is on enhancing producing wells, not drilling new wells, thereby allowing it to optimise PDP revenues and reduce costs. The company derives revenues from the sale of oil, natural gas and natural gas liquids.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.